Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company offers cerebrum, a small molecule platform for CNS small molecule therapies and solidus, an antisense oligonucleotide platform to discover and develop antisense oligonucleotide. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020; and PRAX-050. In addition, the company develops elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080; PRAX-090; and PRAX-100. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Praxis Precision Medicines Inc.

An announcement from Praxis Precision Medicines ( ($PRAX) ) is now available. On December 9, 2025, Praxis Precision Medicines announced the complet...

Praxis Precision Medicines Plans New Drug Application

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Praxis Precision Medicines today and set a price target of $450.00. Rahimi covers t...

Piper Sandler Sticks to Its Buy Rating for Praxis Precision Medicines (PRAX)

An announcement from Praxis Precision Medicines ( ($PRAX) ) is now available. On December 4, 2025, Praxis Precision Medicines announced the success...

Praxis Precision Medicines Shares RADIANT Study Results

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Praxis Precision Medicines (PRAX – Research Report) ...

Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), Protara Therapeutics (TARA)

Jefferies analyst Andrew Tsai maintained a Buy rating on Praxis Precision Medicines today and set a price target of $300.00. Tsai covers the Health...

Jefferies Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)

Looking for top-rated stocks to buy now? Recent analyst updates highlight three companies that have earned Strong Buy ratings from Top Wall Street ...

3 ‘Strong Buy’ Stocks to Buy Today, 12/4/2025, According to Top Analysts

BTIG analyst Thomas Shrader initiated coverage with a Buy rating on Praxis Precision Medicines yesterday and set a price target of $424.00. Shrader...

Praxis Precision Medicines (PRAX) Has a New Rating from BTIG

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY – Research Report), AbSci (ABSI ...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), AbSci (ABSI) and Praxis Precision Medicines (PRAX)

Earnings reports, acquisitions, and other news are leading the top stock market stories for Friday.


Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

Praxis Precision Medicines stock was a hot topic after the company announced plans for a fireside chat.


	A	B	C	D
1	Symbol	Price	Change	Volume
2	PRAX	$268.80	+0.57%	402.80K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PRAX	$268.80	+0.6%	402.80K
3
4
5
6

PRAX

PRAX

Get Praxis Precision Medicines Inc. Data in Excel

Get Praxis Precision Medicines Inc. Data in Excel